AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ALLERGY THERAPEUTICS PLC

Remuneration Information Jul 16, 2018

7477_rns_2018-07-16_2527c1d3-8f3d-47a7-a1e8-1d8b2e964f3f.html

Remuneration Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7205U

Allergy Therapeutics PLC

16 July 2018

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

(Note: Italicised terms have the same meaning as given in the Listing Rules.)

Date: 11 JULY 2018

Name of applicant: ALLERGY THERAPEUTICS PLC
Name of scheme: Allergy Therapeutics plc 2013 Long Term Incentive Plan
Period of return: From: 21 Nov 2017 To: 11 July 2018
Balance of unallotted securities under scheme(s) from previous return: 10,000,000
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): -
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 2,050,848
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 7,949,152
Name of contact: Sara Goldsbrough
Telephone number of contact: +44 (0) 7966 165719

Total Voting Rights

The total number of voting rights of the company is 596,168,616. This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the share capital of the company under the FCA's Disclosure and Transparency Rules. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

BLRSFSSWMFASEIW

Talk to a Data Expert

Have a question? We'll get back to you promptly.